Recent emerging evidence suggests that several ASK1-interacting proteins such as Dickkopf-3 (DKK3), CASP8 and FADD-like apoptosis regulator (CFLAR, known as cFlip), and TNFα-induced protein 3 (TNFAIP3, known as A20) represent attractive therapeutic targets for the prevention and treatment of NAFLD/NASH (41–43). The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatotic liver disease.